Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC9A1 | P19634 | 2/20 | 0.67 |
| ▸ | SLC9A3 | P48764 | 1/20 | 0.67 |
| ▸ | SLC9A2 | Q9UBY0 | 1/20 | 0.67 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6927272 | 0.84 | SLC9A1 (0.63) | SLC9A1SLC9A3SLC9A2 | |
| Eniporide SCHEMBL6619624 | 0.81 | SLC9A1 (1.00) | SLC9A1SLC9A3SLC9A2 | |
| Eniporide SCHEMBL29359307 | 0.81 | SLC9A1 (1.00) | SLC9A1SLC9A3SLC9A2 | |
| Eniporide SCHEMBL29359767 | 0.79 | SLC9A1 (0.95) | SLC9A1SLC9A3SLC9A2 | |
| Eniporide SCHEMBL6619621 | 0.79 | SLC9A1 (0.63) | SLC9A1SLC9A3SLC9A2 | |
| SCHEMBL5190885 | 0.78 | SLC9A1 (0.59) | SLC9A1 | |
| Eniporide SCHEMBL6623628 | 0.78 | SLC9A1 (0.62) | SLC9A1SLC9A3SLC9A2 | |
| SCHEMBL7352153 | 0.78 | SLC9A1 (0.62) | SLC9A1SLC9A3SLC9A2 | |
| SCHEMBL7158966 | 0.78 | SLC9A1 (0.48) | SLC9A1SLC9A3SLC9A2 | |
| SCHEMBL6623631 | 0.74 | SLC9A1 (0.73) | SLC9A1SLC9A3SLC9A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2000066552-A1 | METHOD FOR PRODUCING A BENZOYLGUANIDINE DERIVATIVE | MERCK PATENT GMBH (DE) | 2000-11-09 | — | — | WO | claimed |
| US-6573404-B2 | Intermediates in industrial organic synthesis, e.g. in the preparation of fine chemicals, dyes and crop-protection compositions | MERCK PATENT GMBH (DE) | 2003-06-03 | — | — | US | disclosed |
| US-20030069444-A1 | METHOD FOR PRODUCING ORTHO-ALKYLATED BENZOIC ACID DERIVATIVES | MERCK KGAA (DE) | 2003-04-10 | — | — | US | disclosed |
| US-6515143-B2 | 2-bromo-5-chlorotoluene is reacted with a secondary or tertiary organolithium compound, and carbon dioxide to give 4-chloro-2-methylbenzoic acid | MERCK KGAA (DE) | 2003-02-04 | — | — | US | disclosed |
| US-20020091286-A1 | Method for producing ortho-alkylated benzoic acid derivatives | MERCK GMBH (DE) | 2002-07-11 | — | — | US | disclosed |
| US-6350904-B1 | CATALYTIC CARBOXYLATION OF HALOALKYLBENZENE | MERCK KGAA (DE) | 2002-02-26 | — | — | US | disclosed |
| WO-2001002353-A1 | METHOD FOR PRODUCING A 4-(PYRROLE-1-YL)-BENZOYLGUANIDINE DERIVATIVE | MERCK PATENT GMBH (DE) | 2001-01-11 | — | — | WO | disclosed |
| WO-2000066552-A1 | METHOD FOR PRODUCING A BENZOYLGUANIDINE DERIVATIVE | MERCK PATENT GMBH (DE) | 2000-11-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020091286-A1 | Method for producing ortho-alkylated benzoic acid derivatives | AOC2, OXER1, GABBR2 | SLC9A1 2216/4885SLC9A3 2590/4885SLC9A2 1119/4885 |
| US-20030069444-A1 | METHOD FOR PRODUCING ORTHO-ALKYLATED BENZOIC ACID DERIVATIVES | AOC2, OXER1, GABBR2 | SLC9A1 2216/4885SLC9A3 2590/4885SLC9A2 1119/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.